机译:拯救自体干细胞移植复发多发性骨髓瘤的意义:日本全国回顾性研究
Department of Hematology/Oncology Japan Community Health Care Organization (JCHO) Kyushu Hospital;
Department of Hematology/Oncology Kyushu University Hospital;
Department of Hematology Hara-Sanshin Hospital Fukuoka;
Division of Hematology Saitama Medical Center Jichi Medical University Saitama;
Department of Hematology Japanese Red Cross Society Wakayama Medical Center Wakayama;
Department of Hematology/OncologyTransfusionHemapheresis Center Kurashiki Central Hospital;
Department of Hematology Hiroshima Red Cross HospitalAtomic-Bomb Survivors Hospital Hiroshima;
Division of Hematology Miyagi Cancer Center Natori;
Division of Hematology Department of Medicine Keio University School of Medicine;
Department of Hematology Federation of National Public Service Personnel Mutual Aid Associations;
Division of HematologyOncology Nagoya City University Hospital Nagoya;
Hematopoietic Stem Cell Transplantation Division National Cancer Center Hospital Tokyo;
Japanese Data Center for Hematopoietic Cell Transplantation;
Department of Hematology National Hospital Organization Okayama Medical Center Okayama Japan;
Multiple myeloma; Salvage therapy; Autologous hematopoietic cell transplantation;
机译:拯救自体干细胞移植复发多发性骨髓瘤的意义:日本全国回顾性研究
机译:自体和异种干细胞移植在自体干细胞移植后复发/进展的复制作用疗法
机译:ixazomib在复发性多发性骨髓瘤患者中作为挽救性自体干细胞移植(ASCT)的增强条件疗法以及ASCT后巩固和维持策略的作用(ACCoRd [UK-MRA Myeloma XII]试验): III期随机对照试验
机译:砷救生优于化疗和骨髓移植复发急性突出细胞细胞白血病:来自香港的十年经验
机译:自然杀手细胞回收和疾病结果在多发性骨髓瘤中的自体干细胞移植后
机译:ixazomib在复发性多发性骨髓瘤患者中作为挽救性自体干细胞移植(ASCT)的增强条件疗法以及ASCT后巩固和维持策略的作用(ACCoRd UK-MRA Myeloma XII试验): III期随机对照试验
机译:复发性多发性骨髓瘤患者的第二次自体干细胞移植作为挽救疗法:第一次自体干细胞移植后无疾病间隔时间更长的患者的预后得到改善